Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 17/20 | 0.70 |
| ▸ | SLC2A3 | P11169 | 17/20 | 0.70 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18343270 | 0.93 | SLC2A1 (0.67) | SLC2A1SLC2A3ROCK2ROCK1 | |
| SCHEMBL18343187 | 0.90 | ROCK2 (0.63) | SLC2A1SLC2A3ROCK2ROCK1 | |
| SCHEMBL18343136 | 0.88 | SLC2A3 (0.70) | SLC2A1SLC2A3ROCK2ROCK1 | |
| SCHEMBL20534330 | 0.88 | SLC2A3 (0.68) | SLC2A1SLC2A3ROCK2ROCK1 | |
| SCHEMBL18343208 | 0.87 | SLC2A3 (0.69) | SLC2A1SLC2A3ROCK2ROCK1 | |
| SCHEMBL31173608 | 0.87 | SLC2A1 (0.53) | SLC2A1SLC2A3ROCK2ROCK1 | |
| SCHEMBL27248856 | 0.87 | SLC2A1 (0.53) | SLC2A1SLC2A3ROCK2ROCK1 | |
| SCHEMBL18343244 | 0.87 | ROCK2 (0.60) | SLC2A1SLC2A3ROCK2ROCK1 | |
| SCHEMBL18343302 | 0.87 | ROCK2 (0.59) | SLC2A1SLC2A3ROCK2ROCK1 | |
| SCHEMBL27248805 | 0.87 | SLC2A1 (0.53) | SLC2A1SLC2A3ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988484-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988484-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-04-27 | — | — | US | disclosed |
| US-10729691-B2 | Treatment of infectious diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-10729691-B2 | Treatment of infectious diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORP LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORP LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-10273248-B2 | Glucose uptake inhibitors | Kadmon Corportion, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273248-B2 | Glucose uptake inhibitors | Kadmon Corportion, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180298029-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION LLC (US) | 2018-10-18 | — | — | US | disclosed |
| WO-2016210331-A1 | TREATMENT OF INFECTIOUS DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298029-A1 | GLUCOSE UPTAKE INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | SLC2A1 1/4885SLC2A3 4/4885ROCK2 4260/4885 |
| US-10988484-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A2, SLC2A4 | SLC2A1 1/4885SLC2A3 4/4885ROCK2 4305/4885 |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | SLC2A1, SLC2A4, SLC2A2 | SLC2A1 1/4885SLC2A3 4/4885ROCK2 3943/4885 |
| US-10273248-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A2, SLC2A4 | SLC2A1 1/4885SLC2A3 4/4885ROCK2 4260/4885 |
| US-10729691-B2 | Treatment of infectious diseases with glucose uptake inhibitors | SLC5A1, SLC2A1, SLC2A4 | SLC2A1 2/4885SLC2A3 6/4885ROCK2 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.